We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $177M
1-Year Est. Return 212.06%
This Fund
S&P 500
This Quarter Est. Return
+2.15%
1 Year Est. Return
+212.06%
3 Year Est. Return
+504.78%
5 Year Est. Return
+412.43%
10 Year Est. Return
–
AUM
$177M
AUM Growth
-$804M
Cap. Flow
-$808M
Cap. Flow %
-455.56%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$793M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
1
Phathom Pharmaceuticals
PHAT
$732M
$81M 45.65%
7,464,572
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.09B
$74.9M 42.19%
2,208,639
-465,543
-17% -$15.3M
AURA icon
3
Aura Biosciences
AURA
$764M
$21.6M 12.16%
3,039,892
– –
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-19,963,157
Closed -$793M

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM
OS
Objectivity Squared Charleston, South Carolina $178M AUM 31.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $178M AUM 29.33% 1-Year Est. Return
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Medicxi Ventures Management's Q2 2026 Portfolio in Review

As of Q2 2026, Medicxi Ventures Management held 4 positions worth $177M, down 82% from $982M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $808M in Q2 2026, closing 1 position and reducing 1 holding. Its most notable exit was Centessa Pharmaceuticals, an estimated $793M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $15.3M.
  • Medicxi Ventures Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $793M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $177M portfolio in Q2 2026.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q2 2026.
  • Medicxi Ventures Management's portfolio value fell 82% quarter-over-quarter to $177M.

Based on Medicxi Ventures Management's 13F filing for Q2 2026, filed 4 Aug 2026.